Recent

% | $
Quotes you view appear here for quick access.

Boston Scientific Corporation Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • ma45342312 ma45342312 Feb 3, 2010 9:43 AM Flag

    Timing of Move Rings SALES REVENUE Better Then Estimates

    The recall that you are speaking of only affects devices implanted subpectorially and greater then 95% of devices are implanted subcutaneously. The recall is really a none issue. Cognis and Teligen are simply the smallest, thinnest, longest lasting, most energy efficent devices on the market today. Those are all facts if you do your homework. Plenty of documentation around to support these facts.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Better check your facts... "The recall that you are speaking of only affects devices implanted subpectorially and greater then 95% of devices are implanted subcutaneously. The recall is really a none issue. Cognis and Teligen are simply the smallest, thinnest, longest lasting, most energy efficent devices on the market today. Those are all facts if you do your homework. Plenty of documentation around to support these facts".
      Fact is, the company is up to the same bad behavior when it was Guidant. The Cognis/Teligen issues are NOT isolated to subpectoral implants, rather it covers all devices manufactured since the product has serious quality issues involving header separation. The Heart Rhythm Journal just published a very revealing and specific article involving header separation of a subcutaneous implant, and I promise you that is not a single isolated case. More will follow. The problem here is that BSX was not upfront and forthright about the issue, attempted to hide it behind a specific method of implant, and has blatantly withheld information from its employees, physicians, and patients. Regardless of where or how the product is implanted, the quality and reliability of products this company manufactures has not improved (and is maybe even worse). This is a real problem internally and externally as employee & customer sentiment plummets. There is a point at which consumers and employees must lose all faith and abandon a company. Hard to imagine that point has not yet been reached with BSX.

    • not to mention the FACT that the Lancet study was a biased short term report that ignores the body of work which is far more substantiated that Taxus is a better performing stent....where do these idiots come from?

 
BSX
23.82-0.39(-1.61%)Aug 31 4:01 PMEDT